{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:24:38Z","timestamp":1778599478974,"version":"3.51.4"},"publisher-location":"Chichester, UK","reference-count":95,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001127","type":"reference-entry","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:31:33Z","timestamp":1069367493000},"source":"Crossref","is-referenced-by-count":21,"title":["Dornase alfa for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Ashley P","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,21]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD001127-BIB1|cit1","first-page":"S66","article-title":"Hypertonic saline X recombinant human DNase: a randomised cross-over study in 18 cystic fibrosis patients [abstract]","volume":"3","author":"Adde","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB3|cit2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1569-1993(01)00009-1","article-title":"Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis","volume":"1","author":"Ballmann","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127-BIB2|cit3","series-title":"22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany","first-page":"80","article-title":"Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]","author":"Ballmann","year":"1998"},{"key":"10.1002\/14651858.CD001127-BIB4|cit4","series-title":"Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm","first-page":"147","article-title":"The effect of rhDNase on exercise performance and gas trapping in adults with cystic fibrosis: a randomised controlled trial [abstract]","author":"Dodd","year":"2000"},{"issue":"7","key":"10.1002\/14651858.CD001127-BIB5|cit5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0929-693X(96)81225-5","article-title":"Clinical development of rhDNase in the United States","volume":"2","author":"Eisenberg","year":"1995","journal-title":"Archives de Pediatrie"},{"key":"10.1002\/14651858.CD001127-BIB6|cit6","series-title":"Proceedings of the 36th Annual Conference on Chest Disease; 1993","article-title":"Aerosolised recombinant human DNase reduces pulmonary exacerbations and improves pulmonary function in patients with cystic fibrosis [abstract]","author":"Fuchs","year":"1993"},{"issue":"10","key":"10.1002\/14651858.CD001127-BIB7|cit7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB8|cit8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0266462300009387","article-title":"A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis","volume":"12","author":"Menzin","year":"1996","journal-title":"International Journal of Technology Assessment in Healthcare"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB9|cit9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001127-BIB10|cit10","first-page":"152","article-title":"A summary of the results of the phase III multicenter clinical trial: aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis [abstract]","volume":"Suppl 9","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB11|cit11","first-page":"220","article-title":"Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis","volume":"90","author":"Schulenburg","year":"1995","journal-title":"Medizinische Klinik"},{"issue":"2","key":"10.1002\/14651858.CD001127-BIB12|cit12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/ajrccm.153.2.8564129","article-title":"Effect of rhDNase on airflow obstruction and mucocilary clearance in cystic fibrosis","volume":"153","author":"Laube","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127-BIB13|cit13","first-page":"155","article-title":"A randomized, placebo-controlled trial of the effect of recombinant human DNase (rhDNase) on the deposition homogeneity and mucociliary clearance of radioaerosol in patients with cystic fibrosis [abstract]","volume":"Suppl 9","author":"Laube","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB15|cit14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001127-BIB14|cit15","series-title":"Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium","first-page":"L41","article-title":"rhDNase is well tolerated and effective in cystic fibrosis patients with severe obstructive ling disease [abstract]","year":"1995"},{"key":"10.1002\/14651858.CD001127-BIB16|cit16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1465-9921-6-133","article-title":"Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients","volume":"6","author":"Griese","year":"2005","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD001127-BIB17|cit17","series-title":"Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm","first-page":"P3285","article-title":"Influence of long-term inhaled rhDNase on free and total IL-8 concentration in BAL fluid in cystic fibrosis [abstract]","author":"Jung","year":"2002"},{"key":"10.1002\/14651858.CD001127-BIB18|cit18","first-page":"310","article-title":"Effect of rhDNase on endobronchial inflammation in CF patients with mild lung disease: results of multi-center beat study [abstract]","volume":"Suppl 24","author":"Paul","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001127-BIB19|cit19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/rccm.200307-959OC","article-title":"Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis","volume":"169","author":"Paul","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127-BIB20|cit20","first-page":"383","article-title":"Airway inflammation in CF patients with good pulmonary function - baseline data from the multicenter \"Beat\" study [abstract]","volume":"Suppl 17","author":"Paul","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB21|cit21","series-title":"American Thoracic Society International Conference; 2003 May 16-21; Seattle, USA.","first-page":"Poster E42","article-title":"Longitudinal Evaluation of Airway Inflammation in Stable Cystic Fibrosis (CF) Patients by Bronchoalveolar Lavage (BAL) and Influence rhDNase [abstract]","author":"Paul","year":"2003"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD001127-BIB22|cit22","first-page":"143","article-title":"Dornase alpha in pediatric CF patients with normal lung function - effects on airway inflammation [abstract]","volume":"40","author":"Ratjen","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB23|cit23","first-page":"310","article-title":"Treatment with rhDNase reduces DNA levels in BAL fluid of CF patients with mild lung disease [abstract]","volume":"Suppl 24","author":"Ratjen","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ppul.20134","article-title":"DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha","volume":"39","author":"Ratjen","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB25|cit25","first-page":"318","article-title":"High-resolution CT is more sensitive to longitudinal decline in lung status in young children with CF than pulmonary function tests [abstract]","volume":"Suppl 25","author":"Brody","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB26|cit26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ppul.20088","article-title":"Dornase alpha and exhaled NO in cystic fibrosis","volume":"38","author":"Grasemann","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB27|cit27","first-page":"299","article-title":"A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme\u00ae) in cystic fibrosis patients aged 6-10 years with early lung disease [abstract]","volume":"Suppl 20","author":"Konstan","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001127-BIB28|cit28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD001127-BIB29|cit29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ppul.10136","article-title":"Dornase alfa in early cystic fibrosis lung disease","volume":"34","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB30|cit30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1164\/ajrccm\/148.1.145","article-title":"Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis","volume":"148","author":"Ramsey","year":"1993","journal-title":"American Review of Respiratory Disease"},{"issue":"8865","key":"10.1002\/14651858.CD001127-BIB31|cit31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0140-6736(93)92297-7","article-title":"Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis","volume":"342","author":"Ranasinha","year":"1993","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001127-BIB32|cit32","series-title":"Proceedings of the 11th International Cystic Fibrosis Congress; 1992","first-page":"LBS5","article-title":"A phase 2 double-blind placebo controlled study of the pulmonary function and the safety of aerosolised recombinant human DNase in adults with stable stage cystic fibrosis [abstract]","author":"Ranasinha","year":"1992"},{"issue":"2","key":"10.1002\/14651858.CD001127-BIB33|cit33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/thx.51.2.119","article-title":"In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis","volume":"51","author":"Shah","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001127-BIB34|cit34","first-page":"298","article-title":"Composite CT\/PFT score: an outcome measure which markedly improves sensitivity to change in early cystic fibrosis lung disease [abstract]","volume":"Suppl 24","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB35|cit35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/rccm.200209-1093OC","article-title":"Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease","volume":"168","author":"Robinson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001127-BIB36|cit36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0929-693X(96)81226-7","article-title":"Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement","volume":"2","author":"Hodson","year":"1995","journal-title":"Archives de Pediatrie"},{"issue":"6","key":"10.1002\/14651858.CD001127-BIB37|cit37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1183\/09031936.95.08060954","article-title":"Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001127-BIB38|cit38","first-page":"574S","article-title":"Scanning electron microscopy of cystic fibrosis sputum [abstract]","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001127-BIB39|cit39","first-page":"157","article-title":"Report on a multicentre study using aerosolised recombinant human DNase I in the treatment of cystic fibrosis patients with severe pulmonary disease [abstract]","volume":"Suppl 9","author":"Shah","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001127-BIB40|cit40","first-page":"574S","article-title":"The effects of recombinant human DNase I on sputum DNA content [abstract]","volume":"8","author":"Shah","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB41|cit41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S0266462303000072","article-title":"A cost-effectiveness analysis of rhDNase in children with cystic fibrosis","volume":"19","author":"Grieve","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001127-BIB43|cit42","first-page":"iii84","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis [abstract]","volume":"56","author":"Suri","year":"2001","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD001127-BIB42|cit43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/thorax.57.10.841","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis","volume":"57","author":"Suri","year":"2002","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD001127-BIB44|cit44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.2110015","article-title":"Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis","volume":"166","author":"Suri","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127-BIB45|cit45","first-page":"281","article-title":"Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]","volume":"Suppl 22","author":"Suri","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB46|cit46","first-page":"A75","article-title":"A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis [abstract]","volume":"55","author":"Suri","year":"2000","journal-title":"Thorax"},{"issue":"9290","key":"10.1002\/14651858.CD001127-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001127-BIB48|cit48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2006.05.012","article-title":"Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial","volume":"101","author":"Suri","year":"2007","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001127-BIB49|cit49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ppul.10442","article-title":"Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis","volume":"37","author":"Suri","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB51|cit50","first-page":"125","article-title":"In vivo use of hypertonic saline in CF [abstract]","volume":"Suppl 20","author":"Suri","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB50|cit51","doi-asserted-by":"crossref","unstructured":"Suri R Wallis C Bush A Thompson S Normand C Flather M A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis Health Technology Assessment (HMSO) 2002","DOI":"10.3310\/hta6340"},{"key":"10.1002\/14651858.CD001127-BIB52|cit52","first-page":"154","article-title":"A phase II, double blind, multicenter study of the safety and efficacy of aerosolized recombinant human DNase I in hospitalized patients with CF experiecing acute pulmonary exacerbations [abstract]","volume":"Suppl 9","year":"1993","journal-title":"Pediatric Pulmonology"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001127-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1164\/ajrccm.153.6.8665055","article-title":"Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations","volume":"153","author":"Wilmott","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB54|cit54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1183\/09031936.99.13105399","article-title":"Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group.","volume":"13","author":"Bollert","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001127-BIB55|cit55","first-page":"204","article-title":"Targeted introduction of DNase in Scotland [abstract]","volume":"Suppl 12","author":"Bollert","year":"1995","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001127-BIB56|cit56","first-page":"A72","article-title":"Randomized multicentric double blind study of safety and efficacy of Nacystelyn DPI versus placebo in rhDNase treated cystic fibrosis patients [abstract]","volume":"161","author":"Dab","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001127-BIB57|cit57","series-title":"Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden","first-page":"146","article-title":"Randomised multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]","author":"Malfroot","year":"2000"},{"key":"10.1002\/14651858.CD001127-BIB58|cit58","first-page":"244","article-title":"Randomized multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]","volume":"Suppl 19","author":"Malfroot","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB59|cit59","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80164-5","article-title":"Comparison of Pari LC-Star and -Plus nebulisers delivering 2.5mg recombinant human deoxyribonuclease (rhDNase) [abstract]","volume":"5 Suppl","author":"Elkins","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB60|cit60","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1542\/peds.2005-0308","article-title":"A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis","volume":"116","author":"Fitzgerald","year":"2005","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD001127-BIB61|cit61","first-page":"309","article-title":"Is dornase alfa (pulmozyme) more effective before or after physiotherapy? A cross-over, randomised placebo controlled trial [abstract]","volume":"Suppl 22","author":"Fitzgerald","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB62|cit62","first-page":"310","article-title":"Dornase alpha and physiotherapy - which should be first? A randomised double-blind, placebo-controlled trial in CF adults [abstract]","volume":"Suppl 22","author":"Middleton","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB63|cit63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0188-4409(00)00258-7","article-title":"Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis","volume":"32","author":"Furuya","year":"2001","journal-title":"Archives of Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB64|cit64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/pupt.1997.0072","article-title":"Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum","volume":"10","author":"Griese","year":"1997","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD001127-BIB65|cit65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0300-2977(95)00022-F","article-title":"Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients","volume":"46","author":"Heijerman","year":"1995","journal-title":"The Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD001127-BIB66|cit66","first-page":"273","article-title":"Effect of short course of rhDNase on mucociliary clearance in patients with cystic fibrosis [abstract]","volume":"Suppl 14","author":"Hemming","year":"1997","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB67|cit67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1099-0496(200007)30:1<16::AID-PPUL4>3.0.CO;2-H","article-title":"Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis","volume":"30","author":"Robinson","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD001127-BIB68|cit68","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM199203193261207","article-title":"A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis","volume":"326","author":"Hubbard","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001127-BIB69|cit69","series-title":"American Thoracic Society International Conference; 2006 May 19-24; California, USA","first-page":"A82","article-title":"Aerosol delivery of recombinant human DNase 1. Comparison of a vibrating mesh nebulizer with a jet nebulizer [abstract]","author":"Johnson","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB70|cit70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I","volume":"156","author":"King","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001127-BIB71|cit71","first-page":"1438","article-title":"Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis","volume":"50","author":"Laube","year":"2005","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD001127-BIB72|cit72","first-page":"247","article-title":"Positive expiratory pressure alters aerosol distribution in CF [abstract]","volume":"Suppl 20","author":"Laube","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB73|cit73","first-page":"308","article-title":"Reduction in sputum viscosity using high frequency chest compressions (HFCC) compared to conventional chest physiotherapy (CCP) [abstract]","volume":"Suppl 13","author":"Majaesic","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB74|cit74","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ppul.1061","article-title":"Use of computerized tomography and chest-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than 5 years : A preliminary study","volume":"31","author":"Nasr","year":"2001","journal-title":"Pediatric Pulmology"},{"key":"10.1002\/14651858.CD001127-BIB75|cit75","first-page":"278","article-title":"Aerolized recombinant human DNase in cystic fibrosis patients younger than 5 years of age [abstract]","volume":"Suppl 19","author":"Nasr","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB76|cit76","first-page":"298","article-title":"Quantitative HRCT air trapping analysis in CF subjects with mild lung disease during a pulmozyme intervention study [abstract]","volume":"Suppl 24","author":"Robinson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD001127-BIB77|cit77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0954-6111(95)90126-4","article-title":"Two years of experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis","volume":"89","author":"Shah","year":"1995","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB78|cit78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/thx.50.4.333","article-title":"Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I","volume":"50","author":"Shah","year":"1995","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB79|cit79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1569-1993(03)00090-0","article-title":"DNase in stable cystic fibrosis infants: a pilot study","volume":"2","author":"Berge","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD001127-BIB81|cit80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ppul.20636","article-title":"RhDNase before airway clearance therapy improves airway patency in children with CF","volume":"42","author":"Giessen","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001127-BIB80|cit81","first-page":"S97","article-title":"Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis [abstract]","volume":"4 Suppl","author":"Giessen","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001127-BIB82|cit82","first-page":"285","article-title":"Efficacy of DNase in individual children using the N-of-1 study design [abstract]","volume":"Suppl 19","author":"Weck","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD001127-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archotol.131.12.1097","article-title":"Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease","volume":"31","author":"Cimmino","year":"2005","journal-title":"Archives of Otolaryngology - Head and Neck Surgery"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB84|cit84","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD001127-BIB85|cit85","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001127-BIB86|cit86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jama.1968.03140310070022","article-title":"Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis","volume":"205","author":"Lierberman","year":"1968","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD001127-BIB87|cit87","first-page":"204","article-title":"Respiratory System (Pediatrics)","volume-title":"Cystic Fibrosis","author":"Marshall","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD001127-BIB88|cit88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0266462300009387","article-title":"A multi national economic evaluation of rhDNase in the treatment of cystic fibrosis","volume":"12","author":"Menzin","year":"1996","journal-title":"International Journal of Technology Assessment in Healthcare"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB89|cit89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001127-BIB90|cit90","unstructured":"Hayes P (Royal Liverpool Children's Hospital) Personal communication"},{"issue":"5","key":"10.1002\/14651858.CD001127-BIB91|cit91","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB92|cit92","first-page":"220","article-title":"Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory tract infections in patients with cystic fibrosis","volume":"90","author":"Schulenburg","year":"1995","journal-title":"Medizinische Klinik"},{"issue":"3","key":"10.1002\/14651858.CD001127-BIB93|cit93","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001506.pub2","article-title":"Nebulised hyperonic saline for cystic fibrosis","author":"Wark","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001127-BIB94|cit94","article-title":"Recombinant human deoxyribonuclease for cystic fibrosis","author":"Jones","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001127-BIB95|cit95","article-title":"Deoxyribonuclease for cystic fibrosis","author":"Kearney","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001127\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:02:17Z","timestamp":1682589737000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001127"}},"subtitle":[],"editor":[{"given":"Ashley P","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2003,7,21]]},"references-count":95,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001127","relation":{},"subject":[],"published":{"date-parts":[[2003,7,21]]}}}